Harpoon Medical: Beating-Heart Mitral Valve Repair
Executive Summary
Harpoon Medical's Inc.'s beating heart mitral valve procedure uses an expanded polytetrafluorethylene anchor that replaces the non-functioning natural chordae tendineae. The anchor is inserted via a small incision between the ribs and into the leaflet to eliminate mitral valve regurgitation.
You may also be interested in...
Harpoon Finds Its Whale: Edwards Spends Up To $250m For Beating-Heart Mitral Repair Option
Edwards Lifesciences exercised a 2015 option to buy Harpoon, a spin-off from the University of Maryland's School of Medicine, for $100m up-front and up to $150m more in milestones, to add Harpoon's beating-heart mitral valve surgery technology to its growing pipeline of transcatheter and surgical mitral valve repair and replacement devices. The deal also validates the investing approach of Epidarex Capital, one of Harpoon's early investors, which looks for early-stage medtech opportunities in the Mid-Atlantic states.
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.